Discontinued — last reported Q3 '18
Labcorp Holdings Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) increased by 2.5% to $267.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.6%, from $245.80M to $267.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher values indicate a larger near-term drag on reported earnings due to previous acquisition activity.
This represents the projected non-cash expense related to the amortization of finite-lived intangible assets for the upc...
Companies with high M&A activity in the medical device space typically report significant annual amortization expenses.
finite_lived_intangible_assets_amortization_year_1| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $212.50M | $213.40M | $243.10M | $238.90M | $244.20M | $245.50M | $192.50M | $209.30M | $217.10M | $216.90M | $240.10M | $245.80M | $247.40M | $260.40M | $267.00M |
| QoQ Change | — | +0.4% | +13.9% | -1.7% | +2.2% | +0.5% | -21.6% | +8.7% | +3.7% | -0.1% | +10.7% | +2.4% | +0.7% | +5.3% | +2.5% |
| YoY Change | — | — | — | +12.4% | +14.4% | +1.0% | -19.4% | -14.3% | -11.6% | +12.7% | +14.7% | +13.2% | +14.1% | +8.5% | +8.6% |